Although CAR-T treatments by targeting CD19, CD20, and B-cell maturation antigen (BCMA) have been successful in hematopoietic neoplasm (B cell leukemia and lymphoma and multiple myeloma), leading to five Food and Drug Admiration (FDA) approved therapies since 2017, their efficacies in solid neoplasms have been disappointing. This evidence concerns the gene TNFRSF17 and hematopoietic and lymphoid cell neoplasm.